Follow the latest news and projects about COVID-19 and the European Commission's coronavirus response.

Skip to main content
EnglishEN

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer

Project description

DEENESFRITPL

Novel inhibitor for metastatic prostate and pancreatic cancer

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/prostate cancer

Programme(s)

Topic(s)

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

BEN-GURION UNIVERSITY OF THE NEGEV
Address
.
84105 Beer Sheva
Israel
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000
Website Opens in new window
Contact the organisation Opens in new window

Beneficiaries (1)

BEN-GURION UNIVERSITY OF THE NEGEV
Israel
EU contribution
€ 150 000
Address
.
84105 Beer Sheva
Activity type
Higher or Secondary Education Establishments
Website Opens in new window
Contact the organisation Opens in new window

Share this page

Download

Last update: 30 October 2019
Record number: 225624

Permalink: https://cordis.europa.eu/project/id/875197/

© European Union, 2020